Prostate Cancer Symptoms Tips What is prostate cancer symptoms? We have tips about prostate cancer symptoms

2012 was an exciting year for the Abramson Cancer Center. We are featuring blogs featured on the Focus On Cancer blog that highlight cancer treatment breakthroughs, coping tips and ideas, education and inspiration. Today, we are highlighting photodynamic therapy for mesothelioma.

Penn was the first health system in the Philadelphia area to begin researching the use of PDT to treat cancer. Also known as photoradiation therapy, phototherapy or photochemotherapy, PDT brings together light-sensitive medication with low-level beams of light to destroy cancer cells.

Mesothelioma Treatment with Photodynamic Therapy

When treating patients with mesothelioma or pleural disease, Penn Medicine lung specialists offer more treatment options than most other health systems across the country and around the world.

One of those treatment options is photodynamic therapy (PDT).

Penn was the first health system in the Philadelphia area to begin researching the use of PDT to treat cancer. Also known as photoradiation therapy, phototherapy or photochemotherapy, PDT brings together light-sensitive medication with low-level beams of light to destroy cancer cells.

Mesothelioma is by definition a disease that is multifocal, meaning it occurs in several places in the lining of the lung simultaneously. This has traditionally made surgery as a treatment for mesothelioma difficult and ineffective.

PDT is used during surgery to increase the effectiveness of the treatment. It works by bringing together a light-sensitive medication with low-level beams of light to destroy cancer cells.  The medication is injected into the bloodstream and absorbed by the cancer cells. A light source is then applied to the area being treated. The light causes the drug to react with oxygen to form a chemical that kills the cancer cells. Photodynamic therapy can also work by destroying the blood vessels that feed the tumor.

PDT can only work in areas that the light can actually reach. It is effective in treating mesothelioma because it is a cancer that affects the lining of the lung. During the surgery, the light is applied to the pleural space, or area surrounding the lungs. Penn researchers continue working on ways to improve PDT’s effectiveness.

Associate Professor of Surgery, Joseph Friedberg, MD, is researchering ways PDT is uses to treat cancer, such as combining PDT with gene therapy or with tumor vaccines to stimulate the immune system to fight cancer.

These are the areas of PDT research today at Penn, and in all likelihood, the innovations of tomorrow that will make mesothelioma easier to treat.

The outlook for mesothelioma patients is improving both in terms of quality and quantity of life, but those improvements depend on being treated at a center that has the expertise and experience to develop the individual treatment plans that are essential to obtaining the best outcomes.
 

Would you like to learn more about treatments for mesothelioma and pleural diseases?

The Penn Mesothelioma and Pleural Program offers a true multidisciplinary approach, presenting patients with essentially all treatment options offered worldwide and a number of treatments offered only at Penn such as PDT.

For more information about the Penn Mesothelioma and Pleural Program, call 215-662-9697.

A dedicated patient navigator will assist you with specific questions about mesothelioma and pleural diseases, and can help you schedule an appointment with a Penn specialist.

Helpful links:

• Learn more about the Penn mesothelioma program.
• Learn more about mesothelioma.
• Learn more about treatments for mesothelioma at Penn.
• Find a mesothelioma specialist at Penn.

Penn's Abramson Cancer Center is a national cancer center in Philadelphia providing comprehensive cancer treatment, clinical trials for cancer and is a cancer research center. The National Cancer Institute has designated the Abramson Cancer Center a Comprehensive Cancer Center, one of only 40 such cancer centers in the United States.

Cancer Information From a Reliable Source

Thank you for a fantastic 2012. The Focus On Cancer blog is committed to provide people with cancer and their caregivers educated information from a reliable source, the Abramson Cancer Center at Penn Medicine. Please subscribe to our blog to get updates about new cancer treatments at Penn, credible information from cancer experts at Penn, and inspiration from other people with cancer.

When treating patients with mesothelioma or pleural disease, Penn Medicine lung specialists offer more treatment options than most other health systems across the country and around the world.

One of those treatment options is photodynamic therapy (PDT).

Mesothelioma Treatment with Photodynamic Therapy

Penn was the first health system in the Philadelphia area to begin researching the use of PDT to treat cancer. Also known as photoradiation therapy, phototherapy or photochemotherapy, PDT brings together light-sensitive medication with low-level beams of light to destroy cancer cells.

Mesothelioma is by definition a disease that is multifocal, meaning it occurs in several places in the lining of the lung simultaneously. This has traditionally made surgery as a treatment for mesothelioma difficult and ineffective.

PDT is used during surgery to increase the effectiveness of the treatment. It works by bringing together a light-sensitive medication with low-level beams of light to destroy cancer cells.  The medication is injected into the bloodstream and absorbed by the cancer cells. A light source is then applied to the area being treated. The light causes the drug to react with oxygen to form a chemical that kills the cancer cells. Photodynamic therapy can also work by destroying the blood vessels that feed the tumor.

PDT can only work in areas that the light can actually reach. It is effective in treating mesothelioma because it is a cancer that affects the lining of the lung. During the surgery, the light is applied to the pleural space, or area surrounding the lungs. Penn researchers continue working on ways to improve PDT’s effectiveness.

Associate Professor of Surgery, Joseph Friedberg, MD, is researchering ways PDT is uses to treat cancer, such as combining PDT with gene therapy or with tumor vaccines to stimulate the immune system to fight cancer.

These are the areas of PDT research today at Penn, and in all likelihood, the innovations of tomorrow that will make mesothelioma easier to treat.

The outlook for mesothelioma patients is improving both in terms of quality and quantity of life, but those improvements depend on being treated at a center that has the expertise and experience to develop the individual treatment plans that are essential to obtaining the best outcomes.
 

Would you like to learn more about treatments for mesothelioma and pleural diseases?

The Penn Mesothelioma and Pleural Program offers a true multidisciplinary approach, presenting patients with essentially all treatment options offered worldwide and a number of treatments offered only at Penn such as PDT.

For more information about the Penn Mesothelioma and Pleural Program, call 215-662-9697.

A dedicated patient navigator will assist you with specific questions about mesothelioma and pleural diseases, and can help you schedule an appointment with a Penn specialist.

Helpful links:

• Learn more about the Penn mesothelioma program.
• Learn more about mesothelioma.
• Learn more about treatments for mesothelioma at Penn.
• Find a mesothelioma specialist at Penn.

Penn's Abramson Cancer Center is a national cancer center in Philadelphia providing comprehensive cancer treatment, clinical trials for cancer and is a cancer research center. The National Cancer Institute has designated the Abramson Cancer Center a Comprehensive Cancer Center, one of only 40 such cancer centers in the United States.

Penn thoracic surgeon Joseph Friedberg, MD, recently led research published in the Annals of Thoracic Surgery that found photodynamic light therapy, or PDT, improved median survival rates of patients with mesothelioma to more than 31 months, compared to a median survival rate of 8 months with lung-sparing surgery.

This Sunday, the Philadelphia Inquirer featured a story about Dr. Friedberg and the team of clinicians and researchers at Penn Medicine who are using PDT to treat patients with pleural mesothelioma.

Photodynamic therapy, also known as photoradiation therapy, phototherapy, or photochemotherapy is used to treat certain types of cancer.

It is based on the discovery that certain chemicals known as photosensitizing agents can kill organisms when they are exposed to a particular type of light. PDT destroys cancer cells through the use of a fixed-frequency laser light (an intense narrow beam of light) in combination with a photosensitizing agent

From the Inquirer:

"...for more than two decades, Penn scientists have been doggedly pursuing innovations. They are combining conventional treatments with gene therapy, T-cell therapy, and the laser technology, called photodynamic therapy. Patients come thousands of miles to Penn after exploring their options - or lack thereof."

Read the full article about how Penn is changing the way lung disease is treated.

Would you like to learn more about treatments for mesothelioma and pleural diseases?

The Penn Mesothelioma and Pleural Program offers a true multidisciplinary approach, presenting patients with essentially all treatment options offered worldwide and a number of treatments offered only at Penn such as PDT.

For more information about the Penn Mesothelioma and Pleural Program, call 215-662-9697.

A dedicated patient navigator will assist you with specific questions about mesothelioma and pleural diseases, and can help you schedule an appointment with a Penn specialist.

Helpful links:

• Learn more about the Penn mesothelioma program.
• Learn more about mesothelioma.
• Learn more about treatments for mesothelioma at Penn.
• Find a mesothelioma specialist at Penn.

Mesothelioma is one of the most aggressive and deadliest forms of cancer and is usually caused by exposure to asbestos. Exposure to asbestos typically precedes development of the cancer by anywhere from 10 to 50 years, but once diagnosed, only about 40 percent of U.S. mesothelioma patients survive one year.

Penn Medicine's Mesothelioma and Pleural Program and Penn's Abramson Cancer Center in Philadelphia, PA bring together internationally renowned experts in medical, surgical and radiation oncology and pulmonology who collaborate in the diagnosis, treatment and research of mesothelioma and pleural disease.

In a study published in the Annals of Thoracic Surgery, lead author Joseph Friedberg, MD, co-director of the Penn Mesothelioma and Pleural Program, and Penn thoracic surgeon, found that among patients with malignant pleural mesothelioma, treatment with lung-sparing surgery in combination with photodynamic therapy (PDT) yielded unusually long survival rates, with median survival rates up to two or more years longer than is reported with traditional treatments

Stephen Hahn, MD, is chair of the department of radiation oncology and the Henry K. Pancoast Professor of Radiation Oncology at the Perelman School of Medicine at the University of Pennsylvania. He is board certified in radiation oncology, medical oncology, and internal medicine and is internationally renowned for his work in photodynamic therapy (PDT).

Dr. Hahn recently answered a series of questions related to lung cancer and radiation therapy for TalkAboutHealth.com.

 

 

What is photodynamic therapy for lung cancer?

Photodynamic therapy is a cancer treatment in which a patient receives (typically by vein) a special light sensitive drug followed by the delivery of a specific type of laser light to a tumor. The drug in the tumor is activated by laser light, which kills cancer cells. We can focus the laser light on a tumor and minimize the amount of laser light on the normal tissues thereby limiting side effects. Currently photodynamic therapy is approved by the FDA in lung cancer for the treatment of tumors within the trachea or bronchus (breathing tubes) that are causing obstruction. It is also approved for esophageal cancers that are causing obstruction of the esophagus (swallowing tube) and some precancerous conditions of the esophagus and skin.

When can photodynamic therapy be used to treat cancer?

Photodynamic therapy cannot be used for all cancers because it is not possible to delivery an adequate dose of laser light to some tumors. In other words, they may be inaccessible. At Penn Medicine, we have one of the largest photodynamic therapy research programs in the world and are currently studying its use in patients with a tumor the chest called mesothelioma.

Learn about Treatment for Lung Cancer and Mesothelioma in Philadelphia

At Penn's Abramson Cancer Center, patients with lung cancer have access to every lung cancer and mesothelioma treatment option available, provided by nationally recognized cancer experts.

Penn's expert care and leading-edge treatments give patients with lung cancer the best chance of an excellent outcome.

Have questions about lung cancer treatments offered at Penn's Abramson Cancer Center in Philadelphia?


Helpful links:

• Learn more about the Penn mesothelioma program in Philadelphia. 
• Learn more about treatments for mesothelioma at Penn.
• Find a mesothelioma specialist at Penn.

Christine Wilson, cancer survivor, shares her experiences from the Abramson Cancer Center’s 2011 Focus On Mesothelioma Conference.  In this blog, she recaps highlights from the conference. You can view all the presentations from the conference here.

When treating patients with mesothelioma or pleural disease, Penn Medicine lung specialists offer more treatment options than most other health systems across the country and around the world.

One of those treatment options is photodynamic therapy (PDT).

Mesothelioma Treatment with Photodynamic Therapy

Penn was the first health system in the Philadelphia area to begin researching the use of PDT to treat cancer. Also known as photoradiation therapy, phototherapy or photochemotherapy, PDT brings together light-sensitive medication with low-level beams of light to destroy cancer cells.

Mesothelioma is by definition a disease that is multifocal, meaning it occurs in several places in the lining of the lung simultaneously. This has traditionally made surgery as a treatment for mesothelioma difficult and ineffective.

PDT is used during surgery to increase the effectiveness of the treatment. It works by bringing together a light-sensitive medication with low-level beams of light to destroy cancer cells.  The medication is injected into the bloodstream and absorbed by the cancer cells. A light source is then applied to the area being treated. The light causes the drug to react with oxygen to form a chemical that kills the cancer cells. Photodynamic therapy can also work by destroying the blood vessels that feed the tumor.

PDT can only work in areas that the light can actually reach. It is effective in treating mesothelioma because it is a cancer that affects the lining of the lung. During the surgery, the light is applied to the pleural space, or area surrounding the lungs. Penn researchers continue working on ways to improve PDT’s effectiveness.

Associate Professor of Surgery, Joseph Friedberg, MD, talks about the possibilities researchers are exploring today, such as combining photodynamic therapy with gene therapy or with tumor vaccines to stimulate the immune system to fight cancer. He also speaks of using substances called rare earth phosphors to create tiny nano crystals that can absorb radioactivity and make it possible to deliver targeted radiation therapy and photodynamic therapy at the same time. 

These are the areas of PDT research today at Penn, and in all likelihood, the innovations of tomorrow that will make mesothelioma easier to treat.

The outlook for mesothelioma patients is improving both in terms of quality and quantity of life, but those improvements depend on being treated at a center that has the expertise and experience to develop the individual treatment plans that are essential to obtaining the best outcomes.
 
Learn more about mesothelioma treatment at the Abramson Cancer Center.

Watch all the presentations from the 2011 Focus On Mesothelioma Conference.


Penn's Abramson Cancer Center is a national cancer center in Philadelphia providing comprehensive cancer treatment, clinical trials for cancer and is a cancer research center. The National Cancer Institute has designated the Abramson Cancer Center a Comprehensive Cancer Center, one of only 40 such cancer centers in the United States.

Christine Wilson, cancer survivor, shares her experiences from the Abramson Cancer Center’s 2011 Focus On Lung Cancer Conference. You can view all the presentations from the conference here. In this blog, she discusses new lung cancer treatments available at Penn’s Abramson Cancer Center.

Corey Langer, MD, has been a contributor to the advances that have occurred in treating lung cancer for the last 20 years. He notes that in 1990, a patient diagnosed with advanced lung cancer had few treatment options. And the drugs that were available were highly toxic and generally ineffective.

Today, that picture has improved significantly.

Patients with lung cancer today have the potential for living longer, often years, and enjoying a good quality of life. These improvements are the result of research that has led to a new understanding of the biology of lung cancer, as well as treatment programs that are multidisciplinary and personalized in their approaches.


New Radiation Oncology Treatments for Lung Cancer
For patients with bronchial tumors that can be removed surgically, photodynamic therapy (PDT) has contributed to improved outcomes.

Photodynamic therapy for lung cancer, (PDT) is a radiation oncology treatment that allows physicians to deliver highly targeted doses of anti-cancer drugs while patients are undergoing surgery. PDT is currently used to treat pleural mesothelioma in addition to some lung cancers.

Penn physicians and researchers are working on ways to improve the delivery of photodynamic therapy as well as how to combine it with gene therapy or other radiation oncology therapies for optimal outcomes.

Proton therapy for lung cancer, the most targeted form of radiation therapy, is also showing promise in treating locally advanced lung cancers. Penn has the largest, most comprehensive proton therapy facility in the United States and is actively engaged in developing protocols for the optimal use of this treatment for lung cancer.


New Chemotherapy Treatments for Lung Cancer
For patients who are not surgical candidates or whose cancers recur, the major improvements in treatment are in the form of more effective, less toxic drugs. The most recent therapies target specific gene mutations found in some lung cancer patients.

In 2001, there were no known genetic mutations associated with lung cancer, but today, more than half of the patients with lung cancer have an identifiable gene mutation. This has opened exciting new pathways for treating these cancers.

The most common genetic mutations in lung cancer are the EGRF and KRAS mutations. Recently the EML4/ALK mutation has been found in 5 to 7 percent of patients. Patients who have these mutations often respond very well to targeted therapies. Avastin, which stops the growth of blood vessels that feed the tumor, has also been shown to be effective in treating adenocarcinomas of the lung.

In the last 20 years the options for patients with lung cancer have expanded from few or none to an array of first, second, third and even fourth line therapies, many of which are based on an increasing understanding of the biology of the disease. Lung cancer remains a difficult disease to treat, but the prospects are improving.

Watch all the presentations from the 2011 Focus on Lung Cancer Conference here.